Patent · US Active

Recombinant modified vaccinia virus Ankara influenza vaccine

US9173933B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Josef Weigl · Birkenfeld, DE
Jürgen Hausmann · Gundelfingen, DE
Robin Steigerwald · Munich, DE

Key dates

Filing date	Oct 7, 2011
Grant date	Nov 3, 2015
Priority date	—
Expiry date	Dec 17, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/16234
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention concerns a recombinant modified vaccinia virus Ankara (MVA virus) expressing at least two external influenza virus antigens and/or an epitope of one or more of the at least two antigens and at least two internal influenza virus antigens and/or an epitope of the at least two antigens. The invention, thus, concerns a recombinant MVA virus encoding multiple external and/or internal influenza virus antigens, preferably from multiple influenza virus strains. The invention further concerns the use of said recombinant MVA in preparing a medicament and vaccine for influenza virus. Further encompassed by the present invention are methods, composition and kits.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.